Common Name: estropipate
How does Ogen work?Estropipate belongs to the class of medications known as estrogen replacement therapy. Estrogen is a female hormone that is produced by the ovaries. Estropipate is a type of estrogen. Once menopause is reached, the ovaries produce less estrogen and progesterone, and symptoms of menopause can occur. This drug is an estrogen replacement hormone used for the management of menopausal symptoms such as abnormal uterine bleeding, hot flashes, sweating, and chills. Your doctor may choose to use a medication for conditions other than the ones listed in these drug information articles. If you're unsure why you are taking this medication, contact your doctor.
How should I use Ogen?The dose of estropipate should be adjusted to the minimum amount required to control symptoms. Usually the drug is taken for 21 to 25 days of the month followed by 5 to 7 days of rest. Women who have had a hysterectomy (i.e., they have had their uterus removed) may take the tablets daily. Women who have not had a hysterectomy should take the medication along with a progestogen (such as progesterone or medroxyprogesterone acetate) for 12 to 14 days of each cycle to reduce the risk of endometrial (uterine) cancer. Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor. It is very important that this medication be taken on a regular schedule as prescribed by the doctor. If you miss a dose of this medication take it as soon as you remember it. If it is almost time for your next dose, skip the missed dose and carry on with your regular schedule. Do not double-up on doses.
What form(s) does Ogen come in?Ogen® is available in strengths of 0.625 mg, 1.25 mg, and 2.5 mg. 0.625 mg: Each yellow-coloured, oval, scored tablet, marked with "U" and "3772" on left and right halves, contains estropipate 0.75 mg (calculated as sodium estrone sulfate 0.625 mg). Nonmedicinal ingredients: hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, potassium phosphate dibasic, silicon dioxide, sodium starch glycolate, tromethamine, yellow dye No. 6, and yellow dye No. 10. 1.25 mg: Each peach-coloured, oval, scored tablet, marked with "U" and "3773" on left and right halves, contains estropipate 1.5 mg (calculated as sodium estrone sulfate 1.25 mg). Nonmedicinal ingredients: hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, potassium phosphate dibasic, silicon dioxide, sodium starch glycolate, tromethamine, and yellow dye No. 6. 2.5 mg: Each blue-coloured, oval, scored tablet, marked with "U" and "3774" on left and right halves, contains estropipate 3.0 mg (calculated as sodium estrone sulfate 2.5 mg). Nonmedicinal ingredients: blue dye No. 2, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, potassium phosphate dibasic, silicon dioxide, sodium starch glycolate, and tromethamine.
What should I NOT take with Ogen?Estropipate should not be taken by anyone who: has liver dysfunction or liver disease, especially of the obstructive type has had breast cancer or endometrial cancer, except in special circumstances has endometrial hyperplasia, unless she is also taking progestogen has undiagnosed vaginal bleeding has had a stroke has had coronary thrombosis has classical migraines has had diseases of circulation or clotting has partial or complete loss of vision or double-vision from eye disease related to circulation problems is or may be pregnant
Are there any other precautions or warnings for Ogen?Endometrial cancer: There is evidence from several studies that estrogens, when taken without progestogens, increase the risk of endometrial (uterine) cancer. Taking a progestogen appropriately along with the estrogen reduces this risk to the same level as that of a woman who does not take estrogen. For this reason, all women who have not had their uteruses removed should also take a progestogen if they use estrogens. Breast cancer: Studies indicate an increased risk of breast cancer with long-term use of estrogen replacement therapy. Women who have breast nodules, fibrocystic disease, abnormal mammograms, or a strong family history of breast cancer should approach the use of estrogens with particular caution. Women taking estrogens should have regular breast examinations and should be instructed in breast self-examination. Blood problems: Estrogens should not be used by persons with active thrombophlebitis or thromboembolic disorders (diseases of blood clotting and abnormal circulation), and they should not be used (except in treatment of cancer) by persons with a history of such disorders in association with estrogen use. They should be used with caution by people with cerebral vascular disease or coronary artery disease, and only if they are clearly needed. Some studies have suggested that, for healthy women, there is an increased relative risk of developing deep vein thrombosis or pulmonary embolism when on hormone replacement therapy. Women with severe varicose veins or severe obesity, and those needing to stay in bed for 3 weeks or more are generally considered to be at increased risk of venous thromboembolism (blood clots in the bloodstream). Increased blood pressure is not uncommon in women using this medication. Blood pressure should be monitored with estrogen use, especially if high doses are used. Smoking can increase the risk of blood clots. Women who take estrogen are strongly advised not to smoke. Diabetes: Estrogens may affect blood sugar control. Anyone with diabetes should carefully monitor their blood glucose levels while taking any product containing estrogen. Gallbladder disease: An increased risk of gallbladder disease has been reported in postmenopausal women taking estrogens. Fluid retention: Estrogen may cause fluid retention. Women with heart or kidney dysfunction, epilepsy, or asthma should be particularly careful when taking it. Cholesterol: Oral estrogens can increase triglycerides in the blood. Your physician may check your cholesterol while on estrogen. Fibroids: This medication may worsen fibroids, causing sudden enlargement, pain, or tenderness. If you notice these effects, contact your doctor. Pregnancy: Estrogen should not be used during pregnancy. If you become pregnant while taking this medication, contact your doctor. Breast-feeding: Estrogen is not safe for use during breast-feeding. A decision should be made whether to discontinue nursing or to discontinue the estrogen, taking into account the importance of the medication to the mother. Children: The safety and effectiveness of this medication have not been established for use by children.